XML 46 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segments of Business and Geographic Areas (Tables)
 6 Months Ended
Jul. 01, 2018
Segment Reporting [Abstract]  
Sales By Segment Of Business
SALES BY SEGMENT OF BUSINESS
 
 
Fiscal Second Quarters Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
July 1,
2018
 
July 2,
2017
 
Percent
Change
 
July 1,
2018
 
July 2,
2017
 
Percent Change
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
89

 
113

 
(21.2
)%
 
$
186

 
226

 
(17.7
)%
     International
 
367

 
381

 
(3.7
)
 
727

 
723

 
0.6

     Worldwide
 
456

 
494

 
(7.7
)
 
913

 
949

 
(3.8
)
Beauty
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
637

 
649

 
(1.8
)
 
1,248

 
1,216

 
2.6

     International
 
472

 
427

 
10.5

 
945

 
841

 
12.4

     Worldwide
 
1,109

 
1,076

 
3.1

 
2,193

 
2,057

 
6.6

Oral Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
157

 
150

 
4.7

 
314

 
306

 
2.6

     International
 
236

 
244

 
(3.3
)
 
458

 
450

 
1.8

     Worldwide
 
393

 
394

 
(0.3
)
 
772

 
756

 
2.1

OTC
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
454

 
432

 
5.1

 
919

 
909

 
1.1

     International
 
612

 
574

 
6.6

 
1,219

 
1,110

 
9.8

     Worldwide
 
1,066

 
1,006

 
6.0

 
2,138

 
2,019

 
5.9

Women's Health
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4

 
3

 
33.3

 
7

 
6

 
16.7

     International
 
276

 
273

 
1.1

 
516

 
512

 
0.8

     Worldwide
 
280

 
276

 
1.4

 
523

 
518

 
1.0

Wound Care/Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
135

 
140

 
(3.6
)
 
238

 
238

 
0.0

     International
 
65

 
92

 
(29.3
)
 
125

 
169

 
(26.0
)
     Worldwide
 
200

 
232

 
(13.8
)
 
363

 
407

 
(10.8
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,476

 
1,487

 
(0.7
)
 
2,912

 
2,901

 
0.4

     International
 
2,028

 
1,991

 
1.9

 
3,990

 
3,805

 
4.9

     Worldwide
 
3,504

 
3,478

 
0.7

 
6,902

 
6,706

 
2.9

 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,317

 
2,101

 
10.3

 
4,317

 
4,224

 
2.2

     International
 
1,021

 
858

 
19.0

 
2,063

 
1,665

 
23.9

     Worldwide
 
3,338

 
2,959

 
12.8

 
6,380

 
5,889

 
8.3

     REMICADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
918

 
1,064

 
(13.7
)
 
1,834

 
2,246

 
(18.3
)
     U.S. Exports
 
104

 
127

 
(18.1
)
 
246

 
292

 
(15.8
)
     International
 
298

 
339

 
(12.1
)
 
629

 
664

 
(5.3
)
     Worldwide
 
1,320

 
1,530

 
(13.7
)
 
2,709

 
3,202

 
(15.4
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
274

 
230

 
19.1

 
498

 
459

 
8.5

     International
 
274

 
209

 
31.1

 
568

 
408

 
39.2

     Worldwide
 
548

 
439

 
24.8

 
1,066

 
867

 
23.0

     STELARA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
919

 
680

 
35.1

 
1,571

 
1,227

 
28.0

     International
 
422

 
303

 
39.3

 
831

 
579

 
43.5

     Worldwide
 
1,341

 
983

 
36.4

 
2,402

 
1,806

 
33.0

     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
102

 
—

 
*
 
168

 
—

 
*
     International
 
27

 
7

 
*
 
35

 
14

 
*
     Worldwide
 
129

 
7

 
*
 
203

 
14

 
*
 
 
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
328

 
341

 
(3.8
)
 
661

 
667

 
(0.9
)
     International
 
521

 
451

 
15.5

 
1,018

 
874

 
16.5

     Worldwide
 
849

 
792

 
7.2

 
1,679

 
1,541

 
9.0

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
15

 
17

 
(11.8
)
 
29

 
29

 
0.0

     International
 
196

 
162

 
21.0

 
392

 
299

 
31.1

     Worldwide
 
211

 
179

 
17.9

 
421

 
328

 
28.4

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
277

 
278

 
(0.4
)
 
550

 
537

 
2.4

     International
 
215

 
176

 
22.2

 
420

 
347

 
21.0

     Worldwide
 
492

 
454

 
8.4

 
970

 
884

 
9.7

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
36

 
46

 
(21.7
)
 
82

 
101

 
(18.8
)
     International
 
110

 
113

 
(2.7
)
 
206

 
228

 
(9.6
)
     Worldwide
 
146

 
159

 
(8.2
)
 
288

 
329

 
(12.5
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
639

 
620

 
3.1

 
1,263

 
1,284

 
(1.6
)
     International
 
889

 
847

 
5.0

 
1,824

 
1,680

 
8.6

     Worldwide
 
1,528

 
1,467

 
4.2

 
3,087

 
2,964

 
4.1

     CONCERTA® / Methylphenidate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
68

 
76

 
(10.5
)
 
134

 
184

 
(27.2
)
     International
 
115

 
105

 
9.5

 
222

 
206

 
7.8

     Worldwide
 
183

 
181

 
1.1

 
356

 
390

 
(8.7
)
     INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
438

 
387

 
13.2

 
838

 
759

 
10.4

     International
 
282

 
242

 
16.5

 
578

 
474

 
21.9

     Worldwide
 
720

 
629

 
14.5

 
1,416

 
1,233

 
14.8

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
80

 
91

 
(12.1
)
 
162

 
186

 
(12.9
)
     International
 
108

 
116

 
(6.9
)
 
222

 
228

 
(2.6
)
     Worldwide
 
188

 
207

 
(9.2
)
 
384

 
414

 
(7.2
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
53

 
66

 
(19.7
)
 
129

 
155

 
(16.8
)
     International
 
384

 
384

 
0.0

 
802

 
772

 
3.9

     Worldwide
 
437

 
450

 
(2.9
)
 
931

 
927

 
0.4

 
 
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,085

 
697

 
55.7

 
2,018

 
1,361

 
48.3

     International
 
1,371

 
1,030

 
33.1

 
2,749

 
1,960

 
40.3

     Worldwide
 
2,456

 
1,727

 
42.2

 
4,767

 
3,321

 
43.5

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
298

 
212

 
40.6

 
562

 
413

 
36.1

     International
 
213

 
87

 
*
 
381

 
141

 
*
     Worldwide
 
511

 
299

 
70.9

 
943

 
554

 
70.2

     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
250

 
202

 
23.8

 
477

 
392

 
21.7

     International
 
370

 
248

 
49.2

 
730

 
467

 
56.3

     Worldwide
 
620

 
450

 
37.8

 
1,207

 
859

 
40.5

     VELCADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

 
—

     International
 
280

 
290

 
(3.4
)
 
593

 
570

 
4.0

     Worldwide
 
280

 
290

 
(3.4
)
 
593

 
570

 
4.0

     ZYTIGA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
486

 
241

 
*
 
893

 
474

 
88.4

     International
 
423

 
317

 
33.4

 
861

 
607

 
41.8

     Worldwide
 
909

 
558

 
62.9

 
1,754

 
1,081

 
62.3

     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
51

 
42

 
21.4

 
86

 
82

 
4.9

     International
 
85

 
88

 
(3.4
)
 
184

 
175

 
5.1

     Worldwide
 
136

 
130

 
4.6

 
270

 
257

 
5.1

 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
429

 
37

 
*
 
790

 
37

 
*
     International
 
236

 
48

 
*
 
460

 
48

 
*
     Worldwide
 
665

 
85

 
*
 
1,250

 
85

 
*
     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
180

 
24

 
*
 
329

 
24

 
*
     International
 
131

 
21

 
*
 
253

 
21

 
*
     Worldwide
 
311

 
45

 
*
 
582

 
45

 
*
     TRACLEER®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
71

 
2

 
*
 
139

 
2

 
*
     International
 
72

 
24

 
*
 
144

 
24

 
*
     Worldwide
 
143

 
26

 
*
 
283

 
26

 
*
     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
155

 
8

 
*
 
279

 
8

 
*
     International
 
16

 
1

 
*
 
32

 
1

 
*
     Worldwide
 
171

 
9

 
*
 
311

 
9

 
*
     OTHER 
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
23

 
3

 
*
 
43

 
3

 
*
     International
 
17

 
2

 
*
 
31

 
2

 
*
     Worldwide
 
40

 
5

 
*
 
74

 
5

 
*
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,101

 
1,214

 
(9.3
)
 
2,204

 
2,309

 
(4.5
)
     International
 
417

 
391

 
6.6

 
831

 
771

 
7.8

     Worldwide
 
1,518

 
1,605

 
(5.4
)
 
3,035

 
3,080

 
(1.5
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
679

 
642

 
5.8

 
1,257

 
1,155

 
8.8

     International
 
—

 
—

 
—

 
—

 
—

 
—

     Worldwide
 
679

 
642

 
5.8

 
1,257

 
1,155

 
8.8

     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
169

 
256

 
(34.0
)
 
373

 
503

 
(25.8
)
     International
 
46

 
39

 
17.9

 
90

 
76

 
18.4

     Worldwide
 
215

 
295

 
(27.1
)
 
463

 
579

 
(20.0
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
156

 
174

 
(10.3
)
 
345

 
343

 
0.6

     International
 
80

 
81

 
(1.2
)
 
167

 
159

 
5.0

     Worldwide
 
236

 
255

 
(7.5
)
 
512

 
502

 
2.0

     OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
97

 
142

 
(31.7
)
 
229

 
308

 
(25.6
)
     International
 
291

 
271

 
7.4

 
574

 
536

 
7.1

     Worldwide
 
388

 
413

 
(6.1
)
 
803

 
844

 
(4.9
)
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,899

 
5,010

 
17.7

 
11,253

 
9,882

 
13.9

     International
 
4,455

 
3,625

 
22.9

 
8,945

 
6,998

 
27.8

     Worldwide
 
10,354

 
8,635

 
19.9

 
20,198

 
16,880

 
19.7

 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
129

 
160

 
(19.4
)
 
246

 
314

 
(21.7
)
     International
 
226

 
261

 
(13.4
)
 
448

 
506

 
(11.5
)
     Worldwide
 
355

 
421

 
(15.7
)
 
694

 
820

 
(15.4
)
Diagnostics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

 
—

     International
 
—

 
—

 
—

 
—

 
1

 
*
     Worldwide
 
—

 
—

 
—

 
—

 
1

 
*
Interventional Solutions
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
323

 
285

 
13.3

 
627

 
564

 
11.2

     International
 
344

 
288

 
19.4

 
680

 
558

 
21.9

     Worldwide
 
667

 
573

 
16.4

 
1,307

 
1,122

 
16.5

Orthopaedics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,332

 
1,367

 
(2.6
)
 
2,639

 
2,726

 
(3.2
)
     International
 
930

 
926

 
0.4

 
1,873

 
1,842

 
1.7

     Worldwide
 
2,262

 
2,293

 
(1.4
)
 
4,512

 
4,568

 
(1.2
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
211

 
208

 
1.4

 
420

 
417

 
0.7

     International
 
149

 
142

 
4.9

 
303

 
285

 
6.3

     Worldwide
 
360

 
350

 
2.9

 
723

 
702

 
3.0

     KNEES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
229

 
236

 
(3.0
)
 
457

 
482

 
(5.2
)
     International
 
153

 
149

 
2.7

 
312

 
301

 
3.7

     Worldwide
 
382

 
385

 
(0.8
)
 
769

 
783

 
(1.8
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
394

 
390

 
1.0

 
801

 
781

 
2.6

     International
 
281

 
253

 
11.1

 
570

 
504

 
13.1

     Worldwide
 
675

 
643

 
5.0

 
1,371

 
1,285

 
6.7

     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
498

 
533

 
(6.6
)
 
961

 
1,046

 
(8.1
)
     International
 
347

 
382

 
(9.2
)
 
688

 
752

 
(8.5
)
     Worldwide
 
845

 
915

 
(7.7
)
 
1,649

 
1,798

 
(8.3
)
Surgery
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,022

 
1,012

 
1.0

 
2,015

 
2,007

 
0.4

     International
 
1,493

 
1,372

 
8.8

 
2,923

 
2,648

 
10.4

     Worldwide
 
2,515

 
2,384

 
5.5

 
4,938

 
4,655

 
6.1

     ADVANCED
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
402

 
400

 
0.5

 
795

 
792

 
0.4

     International
 
603

 
533

 
13.1

 
1,176

 
1,018

 
15.5

     Worldwide
 
1,005

 
933

 
7.7

 
1,971

 
1,810

 
8.9

     GENERAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
436

 
423

 
3.1

 
859

 
846

 
1.5

     International
 
733

 
691

 
6.1

 
1,437

 
1,342

 
7.1

     Worldwide
 
1,169

 
1,114

 
4.9

 
2,296

 
2,188

 
4.9

     SPECIALTY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
184

 
189

 
(2.6
)
 
361

 
369

 
(2.2
)
     International
 
157

 
148

 
6.1

 
310

 
288

 
7.6

     Worldwide
 
341

 
337

 
1.2

 
671

 
657

 
2.1

Vision
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
459

 
405

 
13.3

 
899

 
710

 
26.6

     International
 
714

 
650

 
9.8

 
1,389

 
1,143

 
21.5

     Worldwide
 
1,173

 
1,055

 
11.2

 
2,288

 
1,853

 
23.5

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
320

 
274

 
16.8

 
629

 
530

 
18.7

     International
 
524

 
479

 
9.4

 
1,022

 
906

 
12.8

     Worldwide
 
844

 
753

 
12.1

 
1,651

 
1,436

 
15.0

     SURGICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
139

 
131

 
6.1

 
270

 
180

 
50.0

     International
 
190

 
171

 
11.1

 
367

 
237

 
54.9

     Worldwide
 
329

 
302

 
8.9

 
637

 
417

 
52.8

 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,265

 
3,229

 
1.1

 
6,426

 
6,321

 
1.7

     International
 
3,707

 
3,497

 
6.0

 
7,313

 
6,698

 
9.2

     Worldwide
 
6,972

 
6,726

 
3.7

 
13,739

 
13,019

 
5.5

 
 
 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
10,640

 
9,726

 
9.4

 
20,591

 
19,104

 
7.8

     International
 
10,190

 
9,113

 
11.8

 
20,248

 
17,501

 
15.7

     Worldwide
 
$
20,830

 
18,839

 
10.6
 %
 
$
40,839

 
36,605

 
11.6
 %

*Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business
EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
Fiscal Second Quarters Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
July 1,
2018
 
July 2,
2017
 
Percent
Change
 
July 1,
2018
 
July 2,
2017
 
Percent Change
Consumer (1)
 
$
829

 
658

 
26.0
 %
 
$
1,377

 
1,254

 
9.8
 %
Pharmaceutical(2)
 
3,651

 
3,414

 
6.9

 
7,317

 
7,077

 
3.4

Medical Devices(3)
 
796

 
992

 
(19.8
)
 
2,375

 
2,555

 
(7.0
)
Segment earnings before provision for taxes
 
5,276

 
5,064

 
4.2

 
11,069

 
10,886

 
1.7

Less: Expense not allocated to segments (4)
 
303

 
316

 
 
 
615

 
563

 
 

Worldwide income before tax
 
$
4,973

 
4,748

 
4.7
 %
 
$
10,454

 
10,323

 
1.3
 %

(1) Includes a gain of $0.3 billion from the divestiture of NIZORAL® in the fiscal second quarter and six months of 2018. Includes amortization expense of $0.1 billion in the fiscal second quarters and fiscal six months of 2018 and 2017.
 
(2) Includes acquisition costs related to the Actelion acquisition of $0.1 billion and $0.2 billion in the fiscal second quarters of 2018 and 2017, respectively. Includes acquisition costs related to the Actelion acquisition of $0.2 billion in the fiscal six months of 2018 and 2017. Includes a gain of $0.2 billion related to monetization of future royalty receivables in the fiscal second quarter and fiscal six months of 2017. Includes a gain of $0.2 billion in the fiscal six months of 2017 related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes amortization expense of $0.8 billion and $0.2 billion in the fiscal second quarters of 2018 and 2017, respectively. Includes a gain of $0.1 billion from the divestiture of PANCREASE® in the fiscal second quarter and six months of 2018. Includes amortization expense of $1.5 billion and $0.2 billion in the fiscal six months of 2018 and 2017, respectively.
(3) Includes a restructuring related charge of $0.1 billion and $0.1 billion in the fiscal second quarters of 2018 and 2017, respectively. Includes a restructuring related charge of $0.2 billion and $0.3 billion in the fiscal six months of 2018 and 2017, respectively. Includes litigation expense of $0.7 billion and $0.4 billion in the fiscal second quarters and fiscal six months of 2018 and 2017, respectively. Includes an asset impairment of $0.2 billion primarily related to the insulin pump business in the fiscal second quarter and fiscal six months of 2017. Includes amortization expense of $0.3 billion and $0.3 billion in the fiscal second quarters of 2018 and 2017, respectively. Includes amortization expense of $0.5 billion and $0.5 billion in the fiscal six months of 2018 and 2017, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
SALES BY GEOGRAPHIC AREA
 
 
Fiscal Second Quarters Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
July 1, 2018
 
July 2, 2017
 
Percent
Change
 
July 1, 2018
 
July 2, 2017
 
Percent Change
United States
 
$
10,640

 
9,726

 
9.4
%
 
$
20,591

 
19,104

 
7.8
%
Europe
 
4,810

 
4,232

 
13.7

 
9,607

 
8,090

 
18.8

Western Hemisphere, excluding U.S.
 
1,540

 
1,499

 
2.7

 
3,107

 
2,953

 
5.2

Asia-Pacific, Africa
 
3,840

 
3,382

 
13.5

 
7,534

 
6,458

 
16.7

Total
 
$
20,830

 
18,839

 
10.6
%
 
$
40,839

 
36,605

 
11.6
%